Juno Therapeutics

Juno Therapeutics is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling evidence of tumor shrinkage in clinical trials in refractory leukemia and lymphoma conducted to date. Juno's long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases. Juno brings together innovative technologies from some of the world's leading research institutions, including the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children's Research Institute, and The National Cancer Institute. Juno Therapeutics has an exclusive license to the St. Jude Children’s Research Hospital patented technology for CD19 directed product candidates that use 4-1BB, which was developed by Dario Campana, Chihaya Imai, and St. Jude Children’s Research Hospital.
Type
Public
HQ
Seattle, US
Employees
373 (est)
Juno Therapeutics is headquartered in Seattle, US

Key People at Juno Therapeutics

Hans Bishop

Hans Bishop

CEO
Stan Riddell

Stan Riddell

Scientific Co-Founder
Isabelle Rivière

Isabelle Rivière

Scientific co-founder
Michael Jensen

Michael Jensen

Scientific Co-Founder
Phil Greenberg

Phil Greenberg

Scientific Co-Founder
Renier Brentjens

Renier Brentjens

Scientific Co-Founder

Juno Therapeutics Locations

Seattle, US
Waltham, US
Munich, DE
Washington, US
Bothell, US

Juno Therapeutics Metrics

Juno Therapeutics Summary

Market capitalization

$2.01 B

Closing share price

$19.6
Juno Therapeutics's current market capitalization is $2.01 B.

Juno Therapeutics Financials

Juno Therapeutics's revenue is $18.2 M in FY, 2015
FY, 2015

Revenue

$18.2 M

Operating income

$-244 M

Operating expense total

$262 M

Net Income

$-239 M

Operating cash flow

$-104 M

    Juno Therapeutics Market Value History

    Juno Therapeutics Online Presence

    Juno Therapeutics News

    Juno Therapeutics Company Life

    You may also be interested in